Document is current

Article History

Received: 31 July 2023

Accepted: 5 October 2023

First Online: 2 November 2023

Declarations

:

: AVO reports consultant fees from AstraZeneca, Bristol Myers Squibb Company, Pfizer, Merck, Takeda Oncology and Roche; and support for attending meetings and/or travel from Pfizer, Roche, MSD and Janssen. VC reports consultant fees form Roche, BMS, MSD, Astrazeneca, Takeda, Pfizer, Lilly, AMGEN and Sanofi and support for attending meeting and/or travel: Takeda, Roche. ND reports consultant fees from Merck, Mirati, Regeneron, Pfizer, Astrazeneca, DSI, BMS and neogenomics MP reports consultant fees from AstraZeneca, Bristol Myers Squibb Company, Eli LIlly, F. Hoffmann-La Roche, Janssen, Pfizer, MSD, Takeda Oncology and Roche; and support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli LIlly, F. Hoffmann-La Roche, Pierre Fabre Pharmaceuticals, Takeda Oncology and Roche. The ohers authors have no conflicts of interest to declare. This paper is part of the CLARIFY project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160. 7 The contents in this article are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein.

: This study adhered to the ethical principles of the Declaration of Helsinki (2013). The use of information exclusively for scientific purposes was guaranteed, and 6 the right to privacy was protected by omitting the identifying data of the participating subjects. The protocol for this research was presented to and approved by the ethics committee of the Hospital Universitario Puerta de Hierro, Majadahonda, Madrid.

: Informed consent has been obtained from all patients in this study.